

List of published preliminary research relevant to the research program

Darisipudi, Murthy VSN

Peer-reviewed Publications (selection)

1. Mulay SR, Eberhard JN, Pfann V, Marschner JA, **Darisipudi MN**, Daniel C, Romoli S, Desai J, Grigorescu M, Kumar SV, Rathkolb B, Wolf E, Hrabě de Angelis M, Bäuerle T, Dietel B, Wagner CA, Amann K, Eckardt KU, Aronson PS, Anders HJ, Knauf F. 2016. Oxalate-induced chronic kidney disease with its uremic and cardiovascular complications in C57BL/6 mice. *Am J Physiol Renal Physiol* 310:F785-F795
2. Lech M, Lorenz G, Kulkarni OP, Grosser MO, Stigrot N, **Darisipudi MN**, Günthner R, Wintergerst MW, Anz D, Susanti HE, Anders HJ. 2015 NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF- β receptor signaling. *Ann Rheum Dis* 74:2224-35
3. Kumar SV, Kulkarni OP, Mulay SR, **Darisipudi MN**, Romoli S, Thomasova D, Scherbaum CR, Hohenstein B, Hugo C, Müller S, Liapis H, Anders HJ. 2015. Neutrophil Extracellular Trap-Related Extracellular Histones Cause Vascular Necrosis in Severe GN. *J Am Soc Nephrol* 26:2399-413
4. Rupanagudi KV, Kulkarni OP, Lichtnekert J, **Darisipudi MN**, Mulay SR, Schott B, Gruner S, Haap W, Hartmann G, Anders HJ. 2015. Cathepsin S inhibition suppresses systemic lupus erythematosus and lupus nephritis because cathepsin S is essential for MHC class II-mediated CD4 T cell and B cell priming. *Ann Rheum Dis* 74:452-63
5. Kulkarni OP, Hartter I, Mulay SR, Hagemann J, **Darisipudi MN**, Kumar Vr S, Romoli S, Thomasova D, Ryu M, Kobold S, Anders HJ. 2014. Toll-like receptor 4-induced IL-22 accelerates kidney regeneration. *J Am Soc Nephrol* 25:978-89
6. Lichtnekert J, Rupanagudi KV, Kulkarni OP, **Darisipudi MN**, Allam R, Anders HJ. 2011. Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice. *J Immunol* 187:3413-21
7. Lech M, Weidenbusch M, Kulkarni OP, Ryu M, **Darisipudi MN**, Susanti HE, Mittrüecker HW, Mak TW, Anders HJ. 2011. IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production. *J Am Soc Nephrol* 22:1443-52
8. **Darisipudi MN**, Kulkarni OP, Sayyed SG, Ryu M, Migliorini A, Sagrinati C, Parente E, Vater A, Eulberg D, Klussmann S, Romagnani P, Anders HJ. 2011. Dual blockade of the homeostatic chemokine CXCL12 and the proinflammatory chemokine CCL2 has additive protective effects on diabetic kidney disease. *Am J Pathol* 179:116-24